Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN TAZOBACTAM versus PYOPEN.
Piperacillin-Tazobactam vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
4 g intravenously every 4 hours.
None Documented
None Documented
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category A/B
Category C
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic